Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2010

01-10-2010 | Case Report

Pituitary apoplexy in an adrenocorticotropin-producing pituitary macroadenoma

Authors: Serap Baydur Sahin, S. Cetinkalp, M. Erdogan, U. Cavdar, G. Duygulu, F. Saygili, C. Yilmaz, A. G. Ozgen

Published in: Endocrine | Issue 2/2010

Login to get access

Abstract

Adrenocorticotropin (ACTH) producing macroadenomas and pituitary apoplexy are unusual in Cushing’ s disease. A 20-year-old man who had been diagnosed Cushing’ s disease 2 months ago, presented with sudden headache, nausea, and vomiting. His serum cortisol level was 0.4 μg/dl and ACTH level was 23.9 pg/ml. Magnetic resonance imaging of the pituitary gland disclosed a hemorrhage in the pituitary macroadenoma (22 × 19 mm). He was treated with IV methylprednisolone immediately and then the symptoms were relieved within the first day of the treatment. The hemorrhagic lesion was resected by transsphenoidal surgery successfully. Impaired secretion of pituitary hormones may be seen after the pituitary apoplexy. We communicate a case with pituitary apoplexy of an ACTH secreting pituitary macroadenoma, causing acute glucocorticoid insufficiency.
Literature
1.
D.C. Bills, F.B. Meyer, E.R. Laws, Jr., D.H. Davis, M.J. Ebersold, B.W. Scheithauer, D.M. Ilstrup, C.F. Abboud, A retrospective analysis of pituitary apoplexy. Neurosurgery 33(4), 602–608 (1993)CrossRefPubMed
2.
W. Bonicki, A. Kasperlik-Załuska, W. Koszewski, W. Zgliczyński, J. Wisławski, Pituitary apoplexy: endocrine, surgical and oncological emergency Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas. Acta Neurochir. (Wien.) 120(3–4), 118–122 (1993)CrossRef
3.
H.S. Randeva, J. Schoebel, J. Byrne, M. Esiri, C.B. Adams, J.A. Wass, Classical pituitary apoplexy: clinical features, management and outcome. Clin. Endocrinol. (Oxf.) 51(2), 181–188 (1999)CrossRef
4.
L. Sibal, S.G. Ball, V. Connolly, R.A. James, P. Kane, W.F. Kelly, P. Kendall-Taylor, D. Mathias, P. Perros, R. Quinton, B. Vaidya, Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases. Pituitary 7(3), 157–163 (2004)CrossRefPubMed
5.
A.S. Dubuisson, A. Beckers, A. Stevenaert, Classical pituitary tumour apoplexy: clinical features, management and outcomes in a series of 24 patients. Clin. Neurol. Neurosurg. 109(1), 63–70 (2007). Epub 2006 Feb 20CrossRefPubMed
6.
Verrees M, Arafah BM, Selman WR. Pituitary tumor apoplexy: characteristics, treatment, and outcomes. Neurosurg. Focus. 16(4), E6 (2004) (review)
7.
P.L. Semple, M.K. Webb, J.C. de Villiers, E.R. Laws, Jr., Pituitary apoplexy. Neurosurgery 56(1), 65–72 (2005). (discussion 72–73)PubMed
8.
E.H. Nielsen, J. Lindholm, P. Bjerre, J.S. Christiansen, C. Hagen, S. Juul, J. Jørgensen, A. Kruse, P. Laurberg, Frequent occurrence of pituitary apoplexy in patients with non-functioning pituitary adenoma. Clin. Endocrinol. (Oxf.) 64(3), 319–322 (2006)CrossRef
9.
C.A. Rolih, K.P. Ober, Pituitary apoplexy. Endocrinol. Metab. Clin. North Am. 22(2), 291–302 (1993)PubMed
10.
V. Araya, I. Solís, M. Lemp, S. Oviedo, Partial remission of hypercortisolism in Cushing disease after pituitary apoplexy. A case report. Rev. Med. Chil. 126(12), 1497–1501 (1998)PubMed
11.
W.J. Inder, P.J. Hunt, Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management. J. Clin. Endocrinol. Metab. 87(6), 2745–2750 (2002)CrossRefPubMed
12.
A. Krikorian, D. Abdelmannan, W.R. Selman, B.M. Arafah, Cushing disease: use of perioperative serum cortisol measurements in early determination of success following pituitary surgery. Neurosurg. Focus 23(3), E6 (2007)CrossRefPubMed
13.
J.C. Ausiello, J.N. Bruce, P.U. Freda, Postoperative assessment of the patient after transsphenoidal pituitary surgery. Pituitary 11(4), 391–401 (2008)CrossRefPubMed
14.
Y.S. Woo, A.M. Isidori, W.Z. Wat, G.A. Kaltsas, F. Afshar, I. Sabin, P.J. Jenkins, J.P. Monson, G.M. Besser, A.B. Grossman, Clinical and biochemical characteristics of adrenocorticotropin- secreting macroadenomas. J. Clin. Endocrinol. Metab. 90, 4963–4969 (2005)CrossRefPubMed
15.
S. Cannavò, B. Almoto, C. Dall’Asta, S. Corsello, R.M. Lovicu, E. De Menis, F. Trimarchi, B. Ambrosi, Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur. J. Endocrinol. 149(3), 195–200 (2003)CrossRefPubMed
16.
P. Rotman-Pikielny, N. Patronas, D.A. Papanicolaou, Pituitary apoplexy induced by corticotrophin-releasing hormone in a patient with Cushing’s disease. Clin. Endocrinol. (Oxf.) 58(5), 545–549 (2003)CrossRef
17.
B.W. Scheithauer, A.J. Jaap, E. Horvath, K. Kovacs, R.V. Lloyd, F.B. Meyer, E.R. Laws, Jr., W.F. Young, Jr., Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47(3), 723–729 (2000)CrossRefPubMed
18.
R.N. Nawar, D. AbdelMannan, W.R. Selman, B.M. Arafah, Pituitary tumor apoplexy: a review. J. Intensive Care Med. 23(2), 75–90 (2008). ReviewCrossRefPubMed
19.
D.H. Zayour, W.R. Selman, B.M. Arafah, Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: relation to pituitary function. J. Clin. Endocrinol. Metab. 89(11), 5649–5654 (2004)CrossRefPubMed
20.
J.D. Veldhuis, J.M. Hammond, Endocrine function after spontaneous infarction of the human pituitary: report, review, and reappraisal. Endocr. Rev. 1(1), 100–107 (1980)CrossRefPubMed
21.
B.M. Arafah, J.F. Harrington, Z.T. Madhoun, W.R. Selman, Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J. Clin. Endocrinol. Metab. 71(2), 323–328 (1990)CrossRefPubMed
22.
B.M. Arafah, Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 62(6), 1173–1179 (1986)CrossRefPubMed
23.
B.M. Arafah, S.H. Kailani, K.E. Nekl, R.S. Gold, W.R. Selman, Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas. J. Clin. Endocrinol. Metab. 79(2), 348–354 (1994)CrossRefPubMed
24.
B.M. Arafah, D. Prunty, J. Ybarra, M.L. Hlavin, W.R. Selman, The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J. Clin. Endocrinol. Metab. 85(5), 1789–1793 (2000)CrossRefPubMed
25.
E. Vidal, R. Cevallos, J. Vidal, R. Ravon, J.J. Moreau, A.M. Rogues, V. Loustaud, F. Liozon, Twelve cases of pituitary apoplexy. Arch. Intern. Med. 152(9), 1893–1899 (1992)CrossRefPubMed
Metadata
Title
Pituitary apoplexy in an adrenocorticotropin-producing pituitary macroadenoma
Authors
Serap Baydur Sahin
S. Cetinkalp
M. Erdogan
U. Cavdar
G. Duygulu
F. Saygili
C. Yilmaz
A. G. Ozgen
Publication date
01-10-2010
Publisher
Springer US
Published in
Endocrine / Issue 2/2010
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9367-8

Other articles of this Issue 2/2010

Endocrine 2/2010 Go to the issue

Erratum

Erratum to: Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brain

Original Article

Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma

Original Article

A comparison of antineutrophil cytoplasmic antibody prevalence in patients treated and untreated for hyperthyroidism

Original Article

Common melanocortin-3 receptor variants are not associated with obesity, although rs3746619 does influence weight in obese individuals

Original Article

Expression and regulation of FAAP in the mouse epididymis

Original Article

Selective α1-adrenoceptor antagonist (controlled release tablets) in preoperative management of pheochromocytoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits